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Abstract
Vinpocetine, a phosphodiesterase (PDE) type-1 inhibitor, increases cAMP and cGMP levels and is currently used for the
management of cerebrovascular disorders, such as stroke, cerebral hemorrhage, and cognitive dysfunctions. In this
study, we ﬁrst determined that vinpocetine effectively suppressed adipogenesis and lipid accumulation. However, we
questioned which molecular mechanism is involved because the role of PDE in adipogenesis is still controversial.
Vinpocetine decreased adipogenic cell signaling, including the phosphorylation of ERK, AKT, JAK2, and STAT3, and
adipokine secretion, including IL-6, IL-10, and IFN-α. Interestingly, vinpocetine increased the phosphorylation of HSL,
suggesting the induction of the lipolysis pathway. Moreover, vinpocetine increased UCP1 expression via increasing
cAMP and PKA phosphorylation. The administration of vinpocetine with a normal-chow diet (NFD) or a high-fat diet
(HFD) in mice attenuated body weight gain in mice fed both the NFD and HFD. These effects were larger in the HFD-
fed mice, without a difference in food intake. Vinpocetine drastically decreased fat weight and adipocyte cell sizes in
gonadal and inguinal white adipose tissues and in the liver in both diet groups. Serum triacylglycerol levels and fasting
blood glucose levels were reduced by vinpocetine treatment. This study suggested that vinpocetine prevents
adipocyte differentiation through the inhibition of adipogenesis-associated cell signaling in the early stages of
adipogenesis. Moreover, upregulating cAMP levels leads to an increase in lipolysis and UCP1 expression and then
inhibits lipid accumulation. Therefore, we suggest that vinpocetine could be an effective agent for treating obesity, as
well as improving cognition and cardiovascular function in older individuals.
Introduction
The immoderate accumulation of fat tissue, the result of
an imbalance between energy intake and expenditure,
causes obesity1. Obesity is a major worldwide issue that
increases the incidence of type 2 diabetes mellitus, car-
diovascular diseases, hepatosteatosis, hyperlipidemia, and
other chronic diseases2,3 Obesity is the result of a change
in both adipocyte number and the size of individual fat
cells. While adult-onset obesity is generally due to
adipocyte hypertrophy (increased cell size), adipocyte
hyperplasia (increased adipocyte number) mainly occurs
in children and unhealthy obese individuals4. Therefore,
developing an effective way to ameliorate adiposity is an
important goal in metabolic disease research. There have
been efforts by many researchers to ﬁnd anti-obesity
therapeutic targets. However, most of the anti-obesity
agents reported to date are chemical compounds with side
effects, such as diarrhea, vomiting, nausea, and insomnia5.
To overcome these side effects, many scientists have
sought to identify natural compounds that have anti-
adipogenic effects6,7. In this study, we used a screening
approach to identify natural compounds with anti-obesity
effects. First, we purchased a library of 502 natural com-
pounds and administered them to cultured pre-adipocytes
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at 25 μg/ml to study their effects on adipocyte differ-
entiation, especially on the second day of treatment. We
selected anti-obesity compounds through Oil Red O
(ORO) staining. Among the screened compounds, we
excluded compounds known to act as tumor inducers,
anti-cancer drugs, and blood pressure reducers as well as
compounds with cytotoxicity. Finally, we identiﬁed that
vinpocetine has anti-obesity effects based on the results of
ORO staining.
Vinpocetine is a semisynthetic derivative of vincamine,
an alkaloid ﬁrst extracted from the periwinkle plant dur-
ing the late 1960s8,9. It has been demonstrated that vin-
pocetine is a phosphodiesterase type-1 (PDE1) inhibitor
that increases intracellular cGMP and cAMP concentra-
tions, thereby activating protein kinase A and protein
kinase G (PKG), respectively10–12. Vinpocetine relaxes
cerebral smooth muscle cells and ameliorates cerebral
blood ﬂow13,14. Considering its favorable effects of vaso-
dilation and neuro-protection, vinpocetine has been
widely used for decades in the treatment of cere-
brovascular diseases. Vinpocetine ameliorates neuroplas-
ticity via an increase in Ca2+ and cAMP/cGMP levels,
inducing a cascade that causes the phosphorylation and
activation of cAMP responsive element binding protein
(CREB) and serum response factor (SRF). Activation of
CREB or SRFs promotes the expression of neuroplasticity-
associated genes15. Recently, vinpocetine was reported to
inhibit the proliferation of vascular smooth muscle cells
and breast cancer cells16. Furthermore, vinpocetine was
identiﬁed as a potent anti-inﬂammatory agent. It prohibits
NFκB transcription after stimulation of TNFα by blocking
the IκB kinase complex (IKK)17. However, the anti-obesity
effects of vinpocetine have not previously been
investigated.
In this study, we demonstrated the molecular mechan-
isms by which vinpocetine affects adipocyte differentia-
tion and lipid accumulation. We also administered
vinpocetine to mice on a high-fat diet (HFD) and deter-
mined its anti-obesity effect in vivo. Taken together, we




An FDA-approved natural product chemical library was
purchased from Enzo Life Sciences (Farmingdale, NY).
Vinpocetine, isobutylmethylxanthine, dexamethasone,
insulin, and ORO powder were purchased from Sigma
Chemicals (St. Louis, MO).
Cell culture
3T3-L1 cells were maintained and differentiated as
described previously18. Brieﬂy, serum and media were
purchased from Thermo Fisher Scientiﬁc (Waltham,
MA). 3T3-L1 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% calf serum until
conﬂuence. Then, differentiation was induced in DMEM
containing 10% FBS, insulin (1 μg/ml), iso-
butylmethylxanthine (520 μM), and dexamethasone
(1 μM) (MDI). After 2 days, the medium was replaced
with DMEM supplemented with 10% FBS and insulin
(1 μg/ml). Then, DMEM containing 10% FBS without
insulin was replaced every 2 days until day 6.
Cell viability assay
3T3-L1 cells were plated in 12-well plates and incubated
until conﬂuence. Then, conﬂuent 3T3-L1 cells were
treated with vinpocetine for the indicated time. Cell via-
bility was measured using EZ-Cytox (Daeil Lab Services,
Wonju, Korea) according to the manufacturer’s
protocol19,20.
Western blot assay
Cell lysate extractions were prepared with radio-
immunoprecipitation assay buffer (1% Triton X-100, 1%
sodium deoxycholate, 0.1% sodium dodecyl sulfate,
150mM NaCl, 50 mM Tris–HCl, pH 7.5, and 2mM
EDTA, pH 8.0) as described previously21–23. Antibodies
against C/EBPα, C/EBPβ, PPARγ, A-FABP, FASN, AKT,
p-AKT, AMPKα1/2, p-AMPKα1/2, JAK2, p-JAK2, HSL,
and PGC1α were purchased from Santa Cruz Bio-
technology (Dallas, TX). Antibodies against ERK, p-ERK,
STAT3, p-STAT3, p-HSL, PKA, p-PKA, and UCP1 were
obtained from Cell Signaling Technology (Danvers, MA).
The normalization control was anti-β-actin (Santa Cruz
Biotechnology).
cAMP direct immunoassay
Differentiated 3T3L1 cells were incubated in 0.1M HCl
for 10min at room temperature to detach cells from the
plate. The cAMP level was measured from supernatants
using an ELISA kit in accordance with the manufacturer’s
instructions (Enzo Life Science, Farmingdale, NY).
Oxygen consumption rate (OCR) assay
3T3-L1 cells were seeded in an XF24 microplate and
treated with vinpocetine at 2 days after MDI treatment.
After 3 days, the XF24 microplate was incubated in a non-
CO2 incubator for 1 h, and respiration was measured
under basal conditions, followed by the addition of 2.6 μM
oligomycin, 0.5 μM FCCP, and 1 μM rotenone/antimycin
A. OCRs were measured using an XF24 analyzer
(Seashore Bioscience).
ORO staining
Differentiated 3T3-L1 cells were incubated with 10%
formalin for 10 min and washed with distilled water.
Then, the cells were stained with ORO in 60%
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isopropanol. Finally, the ORO stain that bound to the cells
was eluted with 100% isopropanol and measured using the
OD500.
RNA isolation, reverse transcription-polymerase chain
reaction (RT-PCR), and quantitative RT-PCR (qPCR) analysis
For the RT-PCR and qPCR experiments, total mRNA
was isolated from tissue samples and cultured cells using
an RNA lysis reagent (easy-BLUE™, iNtRON Biotechnol-
ogy, Seongnam, Korea) according to the manufacturer’s
instructions. cDNA (1 μg) was synthesized from RNA
using a qPCR RT master mix (Takara Bio, Otsu, Japan).
Real-time RT-PCR was performed using SYBR® Green
master mix and a thermal cycler, both of which
were purchased from Applied Biosystems (Foster City,
CA)21–23. The primers used are described in Supple-
mentary Figure S1.
Mice and diets
Wild-type C57BL6/J male mice were purchased from
Orient Bio Inc. (Gyeonggi, Korea) (permission number for
animal experiments: 2015-0094). For treatment, 10 and
20mg/kg vinpocetine were intraperitoneally injected. For
assessing metabolic parameters, 2-month-old mice were
fed either a normal-chow diet (NFD) or a high-fat chow
diet (HFD, 60% of kcal as fat, OpenSource Diets, New
Brunswick, NJ) with or without vinpocetine for 10 weeks
as described previously18. To conﬁrm the effects of vin-
pocetine treatment, parameters, such as body weight and
food intake were measured. All mouse tissues were frozen
in liquid nitrogen and stored at −80 °C before performing
experiments.
Analysis of serum metabolic parameters
Blood was drawn from the mice as mentioned above
and centrifuged for 10min at 132 × g to obtain serum.
Serum analysis was performed at Seoul Medical Science
Institute, Korea.
Metabolic assays
To perform glucose tolerance tests (GTTs), 1 g/kg glu-
cose (Sigma-Aldrich, St. Louis, MO) was intraperitoneally
injected into the mice, whereas 1 U/kg insulin (Humulin)
was intraperitoneally administered into the mice for the
insulin tolerance tests (ITTs). The blood glucose level was
measured at 0, 15, 30, 60, 90, and 120min after injection.
Morphological analysis of tissues
The gonadal white adipose tissue (gWAT), inguinal
white adipose tissue (iWAT), liver, and brown adipose
tissue (BAT) were ﬁxed in 4% paraformaldehyde for
24–48 h at 4 °C, processed for parafﬁn embedding, and
stained with hematoxylin and eosin (H&E). Cell size was
analyzed using the ImageJ software program.
Statistical analysis
We employed unpaired t-tests and repeated measures
ANOVA to analyze comparisons between two groups.
Statistical analysis was performed using Prism 5 (Graph-
Pad, La Jolla, CA). P-values < 0.05 were considered to be
signiﬁcant.
Results
Vinpocetine inhibits the differentiation of 3T3-L1 cells and
the expression of adipogenesis-associated factors
To conﬁrm the effect of vinpocetine on lipid accumu-
lation, cells were treated with different doses of vinpoce-
tine at 2 days after MDI treatment. Adipogenesis was
measured by ORO staining of lipid droplets and micro-
scopic imaging 6 days after MDI treatment. ORO staining
and microscopy results showed that treatment with vin-
pocetine reduced 3T3-L1 cell differentiation in a dose-
dependent manner. Speciﬁcally, 50 and 100 μg/ml vin-
pocetine were the most effective doses for inhibiting
adipocyte differentiation (Fig. 1a). Vinpocetine also
decreased the protein expression levels of PPARγ, C/
EBPα, and C/EBPβ (three master regulators of
(see ﬁgure on previous page)
Fig. 1 Effects of vinpocetine on MDI-induced adipogenesis in 3T3-L1 cells. a 3T3-L1 cells were treated with 0, 5, 10, 25, 50, or 100 μg/ml
vinpocetine at 2 days after MDI treatment. Then, Oil Red O staining was performed on day 6 as described in the “Materials and methods”, and images
were acquired by microscopy. b Vinpocetine was administered to 3T3-L1 cells at a range of doses, and cell lysates were harvested at 0 and 6 days
after inducing differentiation. Protein expression of PPARγ, C/EBPα, C/EBPβ, and downstream factors, such as FABP4 and fatty acid synthase in 3T3-L1
cells was detected by western blotting. β-actin was used as a load control. c Cytotoxicity in 3T3-L1 preadipocytes treated with up to 100 μg/ml
vinpocetine was measured by MTT assay (n= 3 for each lane). d 3T3-L1 cells were treated with vinpocetine at 50 or 100 μg/ml, and Oil Red O staining
was performed as described in the “Materials and methods”. Cells were differentiated for 6 days. e Lipid accumulation in 3T3-L1 cells was measured
using spectrophotometry as described in the “Materials and methods” (n= 3 for each lane). f, g 3T3-L1 cells were treated with 50 or 100 μg/ml
vinpocetine at 2 days after MDI treatment, and cell lysates were harvested at days 0, 2, 4, and 6 after inducing the differentiation of the cells. The
mRNA expression levels of the genes encoding adipogenesis-associated factors, such as PPARγ, C/EBPα, and C/EBPβ, and downstream factors, such
as FABP4 and fatty acid synthase, were detected by RT-PCR analysis. The protein expression of adipogenesis-associated factors and downstream
factors was detected by western blotting. β-actin was used as a load control. Data are presented as the mean ± standard error of the mean (SD); ns=
not signiﬁcant; **P < 0.01 for untreated control vs. 50 and 100 μg/ml vinpocetine
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adipogenesis) and FASN and FABP4 (downstream factors
of PPARγ) (Fig. 1b). To conﬁrm that the inhibition of
adipocyte differentiation was not due to attenuated cell
viability, a cell viability assay was performed. The effect of
vinpocetine on adipocyte differentiation was not attribu-
table to a decline in cell viability (Fig. 1c).
We performed ORO staining of the cells treated with 50
and 100 μg/ml vinpocetine, and the results showed that
vinpocetine effectively attenuated MDI-mediated 3T3-L1
cell differentiation (Fig. 1d). Furthermore, vinpocetine-
treated adipocytes had 40% less lipid accumulation than
did the dimethyl sulfoxide-treated control adipocytes
(Fig. 1e). Consistently, the protein and mRNA expression
levels of PPARγ, C/EBPα, and C/EBPβ, as well as FABP4
and FASN were markedly reduced in 3T3-L1 cells after
vinpocetine treatment (Fig. 1f, g). Collectively, vinpocetine
inhibits adipocyte differentiation by decreasing the
expression of adipogenesis-associated proteins and genes.
Vinpocetine retards adipocyte differentiation by inhibiting
adipogenesis-associated cell signaling at an early stage
and inducing lipolysis and UCP1 expression at a late stage
We attempted to further investigate whether the inhi-
bitory effect of vinpocetine works at the early or late stage
of adipogenesis. The ORO staining results showed that
vinpocetine retarded all stages of adipocyte differentia-
tion, including the early stage (day 0 to day 2), the late
stage (day 0 to day 6), and after day 6 (Fig. 2a). Con-
sistently, microscopy images showed that vinpocetine
hindered both the early and late stages of adipocyte dif-
ferentiation (Supplementary Figure S2A). Additionally,
lipid accumulation was reduced by vinpocetine at both the
early and late stages of differentiation (Fig. 2b). Further-
more, we investigated how vinpocetine attenuates adipo-
cyte differentiation and lipid accumulation in terms of
mode of function. Cellular signaling molecules, such as
ERK, AKT, AMPK, and JAK2-STAT3, are known to
regulate lipid formation and adipogenesis32. Therefore, we
aimed to survey whether vinpocetine regulates these
signaling pathways. Vinpocetine effectively attenuated the
phosphorylation of AKT, ERK, and JAK2-STAT3, but not
AMPK, at 4 days after MDI induction (Supplementary
Figure S2b). We then investigated whether vinpocetine
prohibited the phosphorylation of signaling molecules
from day 2 to day 3 of adipocyte differentiation (Fig. 2c).
These results showed that vinpocetine reduced the
phosphorylation of adipogenesis-associated signaling
pathways at the early stages of adipocyte differentiation.
We also determined that vinpocetine induces the upre-
gulation of cAMP levels and the phosphorylation of
lipolysis-associated factors (Fig. 2d, e). We conﬁrmed that
the protein expression of UCP1 and PGC-1α, which
induces thermogenesis and reduces lipid accumula-
tion24,25, is augmented in vinpocetine-treated adipocytes
4 and 6 days after MDI treatment (Fig. 2f). OCRs were
also augmented in vinpocetine-treated adipocytes 5 days
after MDI induction (Fig. 2g). Taken together, vinpocetine
represses adipocyte differentiation by inhibiting
adipogenesis-associated cell signaling at the stages of
differentiation and inhibits lipid accumulation by indu-
cing the lipolysis pathway and UCP1 expression.
Vinpocetine-treated mice have reduced body weight, WAT
size, and adipogenesis-associated gene expression
Next, we investigated the anti-obesity effects of vinpo-
cetine. Mice were fed an NFD or an HFD (containing 60%
of kcal as fat) with or without vinpocetine for 10 weeks.
As shown by the photographic data, the amount of gWAT
was lessened in vinpocetine-treated mice, especially in the
HFD-induced obese mice (Fig. 3a). Vinpocetine-treated
mice also had lower body weight in both the NFD-fed and
HFD-fed groups than that of the untreated control mice
(Fig. 3b). The extent of the reduction in body weight was
particularly notable in the HFD-fed mice. However, there
were no signiﬁcant differences in food intake between the
two diet groups (Fig. 3c).
Moreover, we identiﬁed that the vinpocetine-treated
mice had a lower gWAT weight in both the NFD-fed and
(see ﬁgure on previous page)
Fig. 2 Treatment with vinpocetine retards adipocyte differentiation by inhibiting adipogenesis-associated cell signaling at early stages
and inducing lipolysis and UCP1 expression at late stages. a 3T3-L1 cells were treated with 50 or 100 μg/ml vinpocetine from day 0, and Oil Red
O staining was performed as described in the “Materials and methods” on day 2, day 6, or after day 6 of adipocyte differentiation. b 3T3-L1 cells were
treated with 50 or 100 μg/ml vinpocetine, and its effects on the early and late stages of 3T3-L1 differentiation and lipid accumulation were measured
using spectrophotometry as described in the “Materials and methods” (n= 3 for each lane). c 3T3-L1 cells were treated with 50 or 100 μg/ml
vinpocetine on day 2 after inducing differentiation, and cell lysates were harvested at 0, 1, 6, 12, and 24 h. The phosphorylated forms of AKT, ERK,
JAK2, and STAT3 were detected by western blotting. β-actin was used as a load control. d, e 3T3-L1 cells were treated with vinpocetine, and cell
lysates were harvested at 6 days after MDI induction. d The cAMP level was measured using a cAMP direct immunoassay kit as described in the
“Material and methods” (n= 3 for each lane). e The phosphorylated and total forms of ATGL, PKA, and HSL were detected by western blotting. f 3T3-
L1 cells were treated with 100 μg/ml vinpocetine, and cell lysates were harvested at days 4 and 6. The protein expression of UCP1 and PGC-1α was
detected by western blotting. β-actin was used as a load control. g OCR was measured in differentiated 3T3-L1 cells in the presence of 2.6 μM
oligomycin, 0.5 μM FCCP, and 1 μM rotenone/antimycin A (n= 3 for each lane). Data are presented as the mean ± SD; *P < 0.05; **P < 0.01; and
***P < 0.001 for untreated control vs. 50 and 100 μg/ml vinpocetine
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HFD-fed groups (Fig. 3d) and a lower ratio of gWAT
weight to body weight than that of the untreated control
mice (Supplementary Figure S3). For histological analysis,
we performed H&E staining of sectioned gWAT. Reduced
adipocyte sizes in gWAT were detected in the
vinpocetine-treated NFD-fed and HFD-fed mice (Fig. 3e).
We also determined the effect of vinpocetine in iWAT.
The vinpocetine-treated mice had lower iWAT weight in
both the NFD-fed and HFD-fed groups (Fig. 3f) and a
lower ratio of iWAT weight to body weight than that of
control mice (Supplementary Figure S4). Moreover, H&E
staining data showed that adipocyte size in iWAT in the
vinpocetine-treated NFD-fed and HFD-fed mice was
reduced (Fig. 3g). Interestingly, the mRNA expression of
FABP4 and FASN was reduced in gWAT and iWAT in
the vinpocetine-treated HFD-fed mice (Fig. 3h), suggest-
ing that vinpocetine signiﬁcantly reduces lipid accumu-
lation through the downregulation of FABP4 and FASN in
gWAT. Similar to HFD-fed mice, the mRNA expression
of FABP4 and FASN was reduced in vinpocetine-treated
NFD-fed mice (Supplementary Figure S5). Taken toge-
ther, vinpocetine reduces the weight of and cell size in
both gWAT and iWAT by downregulating adipogenesis-
associated gene expression.
Vinpocetine suppresses lipid accumulation in mouse liver
tissue
We determined whether vinpocetine ameliorates lipid
accumulation in the liver tissues of NFD-fed and HFD-fed
mice. We identiﬁed that the liver weight of vinpocetine-
treated mice was lower than that of the control mice, but
there were no signiﬁcant differences in the liver weight to
body weight ratio (Fig. 4a, Supplementary Figure S6).
Next, we performed H&E staining of sectioned liver tis-
sues. As expected, lipid accumulation in liver tissues was
lessened in vinpocetine-treated NFD-fed and HFD-fed
mice (Fig. 4b). The expression of adipogenesis-associated
genes, including FABP4 and FASN, was attenuated in
vinpocetine-treated liver tissues (Fig. 4c). Taken together,
vinpocetine suppresses lipid accumulation in liver tissues.
Vinpocetine induces BAT activation
Similar to its effect in liver tissue, vinpocetine reduced
the weight of BAT in HFD-fed mice to a greater degree
than that in untreated control HFD-fed mice, whereas it
did not affect BAT weight in NFD-fed mice (Fig. 4d). For
histological analysis, we performed H&E staining of sec-
tioned BAT tissues. The results indicated that the lipid
ratio was reduced in BAT sections from HFD-fed mice
(Fig. 4e). However, there were no differences in the ratio
of BAT weight to body weight in HFD-fed mice (Sup-
plementary Figure S7).
We conﬁrmed the protein expression of UCP1 and
PGC-1α (Fig. 4f) and also analyzed the mRNA expression
of UCP1 in BAT (Fig. 4g). Interestingly, vinpocetine sig-
niﬁcantly increased the protein and mRNA expression of
UCP1 in NFD-fed and HFD-fed mice. Taken together, the
results indicate that vinpocetine inhibits lipid accumula-
tion by upregulating the expression of UCP1.
Vinpocetine ameliorates metabolic parameters related to
hyperlipidemia, liver function, and glucose homeostasis
We determined whether vinpocetine might ameliorate
metabolic parameters, such as the levels of TG, FFA as
a blood fat, and ALT as a biomarker for liver health in
the serum of the experimental mice. As expected, vin-
pocetine diminished the levels of TG, FAA, and ALT in
both the NFD-fed and HFD-fed mice (Fig. 5a). Con-
sidering the effects of vinpocetine on glucose home-
ostasis, we performed GTT assays for 120 min.
Clearance of blood glucose was signiﬁcantly faster in
vinpocetine-treated mice than in control mice (Fig. 5b).
Insulin sensitivity was analyzed by ITT. There were no
differences in blood glucose levels between the
vinpocetine-treated NFD-fed mice and the untreated
control NFD-fed mice, but the blood glucose level was
lower in the vinpocetine-treated HFD-fed mice than
in the control HFD-fed mice (Fig. 5c). These data
indicate that vinpocetine improves hyperlipidemia, liver
function, and glucose homeostasis in HFD-induced
obese mice.
(see ﬁgure on previous page)
Fig. 3 Vinpocetine-treated mice have diminished weight and cell size of gWAT, as well as adipogenesis-associated gene expression.
a Vinpocetine was administered to both HFD-fed and NFD-fed mice as described in the “Materials and methods”. b Body weight was measured using
a weighing scale every 2 days. c Food intake was measured by weighing the remaining chow. d Gonadal WAT weight was measured after the 10-
week experimental diet period. e The adipocyte size in gonadal WAT sections was determined by staining with hematoxylin and eosin (H&E). Size
measurements were performed using ImageJ software. f Inguinal WAT weight was measured after the 10-week experimental diet period. g The
adipocyte size of inguinal WAT sections was determined by staining with H&E. Size measurements were performed as above. h Gonadal WAT and
inguinal WAT were collected, and tissue lysates were prepared as described in the “Materials and methods”. The mRNA expression of FABP4 and
FASN was detected by qPCR analysis. β-actin was used as a normalization control. Data are presented as the mean ± SD; *P < 0.05 and ***P < 0.001 for
untreated control vs. 10 and 20mg/kg vinpocetine (unpaired t-tests). ###P < 0.0001 for untreated control vs. 10 and 20mg/kg vinpocetine (repeated
measures ANOVA)
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Vinpocetine hampers the secretion of adipokines in vitro
and in vivo
Because we initially identiﬁed that vinpocetine inhibited
the activation of the STAT3 pathway (Fig. 2d), we hypo-
thesized that vinpocetine might downregulate cytokines,
such as IL-6, IL-10, and IFN-α, in 3T3-L1 cells and in the
WAT of HFD-fed mice. The mRNA expression of
cytokine-encoding genes, including IL-6, IL-10, and IFN-
α, was markedly diminished by vinpocetine in 3T3-L1
cells (Fig. 6a) and in the WAT of HFD-fed mice (Fig. 6b).
These data show that vinpocetine inhibits the activation
of adipokines both in vitro and in vivo.
Discussion
In this study, we demonstrated that vinpocetine has
pronounced effects of inhibiting adipocyte differentiation
and reducing lipid accumulation in 3T3-L1 cells in vitro
and in HFD-fed mice in vivo (Fig. 6c). Vinpocetine has
been widely used as a drug in Eastern Europe for the
treatment of cerebrovascular disorders and age-related
memory impairment14,26, and it is marketed as a supple-
ment for vasodilation and as a nootropic for the
improvement of memory27,28. Vinpocetine, a derivative of
the vinca alkaloid vincamine, is a known PDE1 inhibitor
that acts to increase the intracellular levels of cAMP and
cGMP, thereby activating protein kinase A and
PKG11,12,15.
First, we conﬁrmed that vinpocetine exerts an inhi-
bitory effect on adipogenesis-associated cell signaling at
the early stage of adipocyte differentiation. However, the
cAMP-dependent mechanism is essential during the
early stage of adipocyte differentiation. Usually,
researchers treat 3T3-L1 cells with 3-isobutyl-1-
methylxanthine (IBMX), a nonselective PDE inhibitor,
to activate CREB and induce downstream adipogenic
factors, such as CCAAT/enhancer-binding protein
alpha (C/EBPα) and peroxisome proliferator-activated
receptor γ29,30. This suggests that inhibition of PDE
is important to initiate adipogenesis and lipid
accumulation in adipocytes. Therefore, we determined
which signaling pathways were affected by vinpocetine
treatment. Previously, vinpocetine was shown to
attenuate the phosphorylation of AKT and ERK1/2,
which are molecules related to the MAPK signaling
pathway14,19,31. As a result, vinpocetine reduced the
phosphorylation of AKT and ERK1/2 in the progression
of early adipocyte differentiation, but it did not affect
the phosphorylation of AMPK. Moreover, it has been
reported that rapid activation of JAK2-STAT3 signaling
is elicited upon the induction of adipogenesis32. STAT3
is activated within 2 h after adipogenic induction, at
which point phosphorylated STAT3 translocates from
the cytoplasm to the nucleus33. Upon the activation of
JAK2-STAT3 signaling, STAT3 regulates the tran-
scription of CEBP by binding to the distal region of its
promoter in the early stage of adipogenesis. We thought
that vinpocetine may act as a STAT3 inhibitor and
found that vinpocetine blocks the phosphorylation of
JAK2 and STAT3. It is also known that the expression of
inﬂammatory cytokines, such as IL-6, IL-10, and IFN-α
is greatly inﬂuenced by STAT3 signaling34,35. There is
an enhanced secretion of some interleukins and
inﬂammatory cytokines in the adipose tissue of obese
individuals, as well as an increased circulating level of
many cytokines36. Adipocytes secrete cytokines such as
IL-6, IL-10, and IFN-α36. IL-6, IL-10, and IFN-α are
among the upstream factors of STAT3. We also iden-
tiﬁed that the expression of the genes encoding IL-6, IL-
10, and IFN-α was inhibited by vinpocetine, suggesting
that these cytokines may regulate one another in an
autocrine manner. FABP4 is a major target gene of
PPARγ and encodes a lipid transporter called aP237.
PPARγ induces FABP4 expression in adipocytes and
macrophages. FABP4 is implicated in the development
of insulin resistance, atherosclerosis, non-alcoholic fatty
liver disease, and obesity37. In the progression of de
novo lipogenesis, FASN catalyzes the de novo synthesis
of long-chain fatty acids from acetyl-coenzyme A and
(see ﬁgure on previous page)
Fig. 4 Vinpocetine retards lipid accumulation in mouse liver tissues and BAT. Vinpocetine was intraperitoneally injected into HFD mice, as
described in the “Materials and methods”. a Both NFD-fed and HFD-fed mice were sacriﬁced after the 10-week experimental diet period. Then, the
liver weight of these mice was measured. b H&E staining of liver sections was performed in each indicated group treated with or without vinpocetine
for 10 weeks as described in the “Materials and methods”. c Liver tissues were collected, and tissue lysates were prepared as described in the
“Materials and methods”. The mRNA expression of FABP4 and FASN was detected by qPCR analysis. β-actin was used as a normalization control.
d Both NFD-fed and HFD-fed mice were sacriﬁced after the 10-week experimental diet period. Then, the BAT weight was measured using a weighing
scale. e H&E staining of BAT sections from mice was performed in the indicated group treated with or without vinpocetine for 10 weeks as described
in the “Materials and methods.” f BAT was collected, and tissue lysate was prepared as described in the “Materials and methods” The protein
expression of UCP1 and PGC-1α was detected by western blotting. β-actin was used as a load control. g BAT was collected, and tissue lysate was
prepared as described in the “Materials and methods”. The mRNA expression of UCP1 was detected by qPCR analysis. β-actin was used as a
normalization control. Data are presented as the mean ± SD (n= 4 for NFD-fed mice and n= 8 for HFD-fed mice); *P < 0.05, **P < 0.01, and ***P <
0.001 for untreated control vs. 10 and 20 mg/kg vinpocetine
Kim et al. Experimental & Molecular Medicine            (2019) 51:5 Page 10 of 15
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
Fig. 5 Vinpocetine improves serum metabolic parameters and glucose homeostasis. a Serum analyses of TG, FFA, and ALT were performed as
described in the “Materials and methods”. b For glucose tolerance tests, 1 g/kg glucose was intraperitoneally injected into both the NFD-fed and HFD-
fed mice. c For insulin tolerance tests, 1 U/kg insulin was intraperitoneally administered into both the NFD-fed and HFD-fed mice. The blood glucose
level was measured at different time points as described in the “Material and methods”. Data are presented as the mean ± SD (n= 4 for NFD-fed mice
and n= 8 for HFD-fed mice) *P < 0.05; **P < 0.01; and ***P < 0.001 for untreated control vs. 10 and 20mg/kg vinpocetine
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Fig. 6 (See legend on next page.)
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malonyl-coenzyme A, and an increase in its expression
has been reported in obesity38,39. As FABP4 and FASN
are involved in lipid accumulation in adipocytes, WAT,
and the liver, we investigated whether vinpocetine reg-
ulates the expression of FABP4 and FASN. As shown by
our data, vinpocetine is likely to reduce the expression
of FABP4 and FASN. Previously, we reported that
galectin-3 regulates PPARγ and is involved in the for-
mation of WAT18. Similarly, we tried to determine
whether vinpocetine can reduce WAT formation as well
as lipid accumulation in liver tissue. We intraper-
itoneally administered vinpocetine into both NFD-fed
and HFD-fed mice to conﬁrm the attenuation of WAT
formation and the reduced expression of FABP4, FASN,
and cytokine-encoding genes, such as IL-6, IL-10, and
IFN-α. Lipid accumulation in the liver was decreased.
These results suggested that vinpocetine blocks adipo-
genesis initiation through inhibition of adipogenic cell
signaling rather than inhibition of PDE.
However, we still have an interest in the role of vin-
pocetine as a PDE1 inhibitor in adipocytes and lipid
accumulation. The PDE family inhibitors block hydro-
lysis of intracellular cAMP/cGMP, induce transcrip-
tional cascades associated with CREB, and increase or
decrease of Ca2+ levels15. PDE3 inhibitors hydrolyze
cGMP and relax vascular and airway smooth muscle,
prohibit platelet aggregation and promote lipolysis40,41.
Additionally, a PDE5 inhibitor has been known to cure
erectile dysfunction. The PDE5 inhibitor sildenaﬁl
increases the level of intracellular cGMP and triggers
penile erection. cGMP activates cGMP-dependent PKG,
which phosphorylates several proteins. These phos-
phorylated proteins cause reduced intracellular Ca2+
levels and a relaxation of arterial and trabecular smooth
muscle, leading to arterial dilatation, venous constric-
tion, and the rigidity of penile erection42,43. We also
found that upregulated cAMP levels could increase the
phosphorylation of protein kinase (PKA)44 and that
activated PKA could activate hormone-sensitive lipase
(HSL)45 and adipose triglyceride lipase (ATGL)46.
Therefore, we questioned whether PDE1 inhibitors
stimulate the lipolysis signal pathway. We determined
here that vinpocetine upregulated cAMP levels in adi-
pocyte cells and consequently increased PKA phos-
phorylation and HSL and ATGL protein levels.
Unlike the lipolysis pathway, we also found that the
protein and mRNA levels of UCP1 were increased in
vinpocetine-treated adipocytes and BAT. Vinpocetine
treatment in adipocytes also increased oxygen consump-
tion, suggesting that vinpocetine considerably triggers
BAT activation. It was documented that PDE3 and PED4
isozyme-selective inhibitors increase intracellular cAMP
levels, thereby inducing the upregulation of the lipolysis
pathway and UCP1 expression47. They mentioned that
the induction of UCP1 or lipolysis was not altered by the
inhibition of PDE1, PDE2, or PDE8A. However, we
identiﬁed that vinpocetine promotes the lipolysis pathway
and UCP1 expression at the late stages of adipocyte dif-
ferentiation. We hypothesize that the effect of vinpocetine
on the increase in UCP1 expression may be caused by the
downregulation of adipogenic cell signaling and the
upregulation of cAMP levels.
Furthermore, insulin sensitivity was improved by vin-
pocetine. There is some evidence for the relationship
between vinpocetine and glucose homeostasis. PDE1C
downregulates glucose-induced insulin secretion48.
PDE3B-overexpressing mice have insulin resistance, islet
dysfunction, and glucose intolerance49. Vinpocetine might
regulate insulin sensitivity through a PDE inhibitor, as in
previous studies. An increase in pro-inﬂammatory cyto-
kines in adipose tissues is known to induce insulin resis-
tance. Because vinpocetine has an anti-inﬂammatory
effect, insulin resistance could be improved by reducing
the level of inﬂammatory cytokines in adipose tissues. The
food intake of NFD-fed and HFD-fed mice did not differ
between the vinpocetine-treated and untreated groups. As
a result, the effect of vinpocetine was independent of food
intake, and there was no suggestion that longer-term
vinpocetine treatment would be lethal in mice. Moreover,
vinpocetine also reduced the body weight of NFD-fed
mice, suggesting that vinpocetine could be a promising
agent for the prevention of obesity.
(see ﬁgure on previous page)
Fig. 6 Vinpocetine inhibits the secretion of adipokines in vitro and in vivo. a 3T3-L1 cells were treated with 50 or 100 μg/ml vinpocetine on day
2 after inducing differentiation, and cell lysates were harvested at the 6, 12, and 24-h time points. The mRNA expression of Il-10, IL-6, and IFN-α was
detected by qPCR analysis. β-actin was used as a normalization control. b Vinpocetine was administered to both the HFD-fed and NFD-fed mice, as
described in the “Materials and methods”. Gonadal WAT and inguinal WAT were collected, and tissue lysates were prepared as described in the
“Materials and methods”. The mRNA expression of IL-10, IL-6, and IFN-α was detected by qPCR analysis. β-actin was used as a normalization control.
Data are presented as the mean ± SD; *P < 0.05 and ***P < 0.001 for untreated control vs. 50 and 100 μg/ml vinpocetine. Data are presented as the
mean ± SD (n= 4 for NFD-fed mice and n= 8 for HFD-fed mice); *P < 0.05; **P < 0.01; and ***P < 0.001 for untreated control vs. 10 and 20mg/kg
vinpocetine. c Schematic representation of the mechanism of action for vinpocetine
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In summary, we demonstrated that vinpocetine attenu-
ates adipogenesis-associated cell signaling pathways at the
early stage of differentiation and facilitates lipolysis path-
ways at the late stage of differentiation. Second, we identi-
ﬁed that the UCP1 level is augmented in adipocytes and
BAT by vinpocetine. Furthermore, it is likely to reduce body
weight by inhibiting FABP4 and FASN expression and
cytokine secretion. However, further study is needed to
investigate the detailed mechanism underlying the anti-
obesity effects of vinpocetine. Taken together, we showed in
this study that vinpocetine has signiﬁcant inhibitory effects
on adipocyte differentiation and lipid accumulation. We
further suggest that the administration of vinpocetine could
reduce the incidence of diseases, such as obesity and dia-
betes, and further clinical studies are warranted to investi-
gate its practical application.
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